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The reticulum cell sarcoma (RCS) 1 of SJL/J mice has been shown to express alien 
histocompatibility  membrane  antigens  (1,  2).  This  form  of tumor  antigen  is,  by 
definition, present on cancerous, but not normal, syngeneic tissues. However, it differs 
from  other  forms  of tumor-associated  antigens  because  it  is  a  normal  membrane 
component of one or more strains allogeneic to the host  (3).  In the case of the RCS, 
both antibody and cytotoxic lymphocytes directed against syngeneic H-2  s or allogeneic 
H-2  a determinants  react strongly with an  in vitro cultured  RCS.  Weak reactivities 
with  anti-H2  b cytotoxic  lymphocytes  have  also  been  seen  in  these  neoplasms.  In 
contrast to the results found with the in vitro cultured  RCS lines, in vivo passaged 
lines have previously shown no detectable alien histocompatibility antigens as recog- 
nized by specific cytotoxic lymphocytes. Furthermore, specific antibody could detect 
only specificities of the H-2  a haplotype and no H-2  b specificities (1). 
An additional trait of the RCS is that it readily induces a syngeneic host immune 
response  (4).  Proliferation  of Ly  1+23 -  T  lymphocytes can  be  induced  in  mixed 
lymphocyte-tumor in vitro cultures  (5).  Lymphocytes can also be induced  to prolif- 
eration  in  vivo by  immunization  with  irradiated  tumors  (6).  Specific  cytotoxicity 
against  the tumor has been demonstrated  when  the in  vitro RCS lines are used  as 
stimulators in mixed lymphocyte-tumor cultures and as targets in cytotoxic assays (1). 
In addition,  syngeneic T  lymphocytes have been induced  to cytotoxicity against  in 
vivo passaged RCS  by special hyperimmunization  regimens  (7).  In primary mixed 
lymphocyte-tumor cultures, in vivo passaged RCS and spontaneous RCS have been 
shown to induce only T  lymphocyte proliferation and no detectable cytotoxicity. 
Little is known of the antigenic determinants on the RCS that are involved in the 
host anti-tumor immune response. Earlier work found that antisera directed against 
syngeneic  IA-encoded  products  (i.e.,  anti-Ia.4)  could  inhibit  the  SjL/j  anti-RCS 
proliferative response. This suggested that host responsiveness was induced via inter- 
action with syngeneic Ia molecules (8).  In that study, an in vivo passaged RCS was 
used, so there was no detectable cytotoxicity by the anti-tumor effector lymphocytes. 
Conversely, another investigation found that syngeneic anti-RCS cytotoxic lympho- 
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cytes, induced by an in vitro cultured RCS  line, could lyse not only the tumor,  but 
also targets expressing H-2  a  alloantigens (1).  The  reasons  for this apparent  conflict 
have  previously remained unresolved.  Further studies of antigen recognition by the 
noncytotoxic  effector  lymphocytes,  primed  against  syngeneic  in  vivo  passaged  or 
spontaneous RCS, have been severely hampered because good quantitative assays do 
not exist. 
We  have  found,  however,  that  noncytotoxic anti-RCS  effector lymphocytes can 
recognize and specifically bind to the RCS, despite the absence of subsequent cytolysis. 
This  assay  of  lymphocyte-target  cell  binding  was  used  to  identify  the  antigens 
recognized  by  the  noncytotoxic  syngeneic  effectors.  Evidence  was  obtained  that 
indicated that the alien histocompatibility antigens found on the RCS of SJL/J mice 
are  intimately involved in  the  syngeneic host  immune  recognition.  Furthermore,  a 
role for syngeneic Ia molecules was also found. Syngeneic lymphocytes primed against 
the RCS could bind not only to the RCS, but also to normal allogeneic spleen cells. 
Genetic mapping with congenic recombinant mice and monoclonal anti-Ia. 7 antibody 
treatment further examined the nature of the alien molecules expressed on the RCS 
and  recognized  by  the  anti-tumor  effectors.  The  results  indicate  that  the  alien 
molecule may be a hybrid Ia molecule consisting of a syngeneic normally unexpressed 
IA~-encoded ~-chain in association with an alien a-chain encoded within IE. Hybrid 
Ia  molecules  have  been  identified  on  normal  cells  of  many  haplotypes  (9-11). 
However, expression of these molecules on the RCS was unexpected because they are 
not normal membrane constituents of SJL/J cells. 
Materials and  Methods 
Mice.  Animals of both sexes at 6-10 wk of age were used in all experiments. With a  few 
exceptions, all strains were purchased  from  The Jackson  Laboratory (Bar Harbor,  Maine). 
Animals of strains B 10.OL and B 10.A were bred in our facility from stock kindly provided by 
Dr. Donald C. Shreffler (Washington University, St. Louis, Mo.). B10.S, D2.GD and  (B10.A 
×  B10.GD)FI mice were a  generous gift from Dr. Walter Urba and Dr. Linda Wicker in the 
laboratory of Dr. William Hildemann (University of California, Los Angeles). B 10.S(9R) and 
BI0.GD  mice  came  from  the  laboratory of Dr.  Eli  Sercarz  (University of California,  Los 
Angeles). 
Tumors.  All RCS used in this work arose spontaneously from SJL/J mice of 6 mo- 1 yr of 
age. The RCS-LA16 line was maintained in vivo by serial passage in young SJL/J animals. 
This line has been found to be derived solely from SJL/J mice by analysis of the polymorphic 
variants of both phosphoglucomutase and glutathione reductase. The in vitro line, RCS-LA6b, 
was maintained in continuous cell culture. It was grown as a single cell suspension in RPMI- 
1640 supplemented with 10% fetal calf serum (FCS) (Grand Island Biological Co., N. Y.) and 
1.8 ×  10  -4 M reduced glutathione (Sigma Chemical Co., St. Louis, Mo.). A primary spontaneous 
RCS was removed from the mesenteric lymph node of an animal  11  mo of age. It was used 
immediately or cryogenically preserved. This line has been termed RCS-LA30. 
Antisera.  The monoclonal anti-Ia.7 antibody was a generous gift from Dr. U. Hammerling 
(Sloan-Kettering Institute for Cancer Research, New York) and was classified as number 13/18 
in  his laboratory. The  hybridoma anti-Thy  1.2 antiserum was derived from ascitic fluid of 
pristane-pretreated BALB/c mice that had been injected with the cell line H022-1. This line 
was obtained from the Cell Distribution Center at The Salk Institute, La Jolla, Calif. Detailed 
methodology has been described elsewhere (12). All sera were stored at -70°C. 
Preparation of Lymphocytes and  RCS.  Responding  lymphocytes  were  derived  from  either 
SJL/J mesenteric lymph nodes or CBA spleens. All nontumor target cells were from the spleens 
of normal animals of the appropriate strain. The  particular tissue  (spleen, lymph node, or 
cancerous lymph node)  was removed and  minced in  Hanks' balanced salt solution (HBSS; 
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repeated passages through a  12-ml syringe, and finally the preparation  was filtered through a 
narrow meshed nylon screen. Erythrocytes in the spleen cell preparations were lysed by a  15-s 
treatment  in distilled water, followed by the addition of an equal volume of 2-X concentrated 
HBSS. 
In  Vitro Cultures.  96 well microtiter plates  (Falcon 3042,  Falcon Labware,  Div. of Becton, 
Dickinson and Co., Oxnard,  Calif.) were used throughout.  To each well, the appropriate  cell 
mixture  was  added  in 0.2  ml  RPMI-1640  that  had  been  supplemented  with  10%  fetal calf 
serum  (RPMI-1640/10%  FCS), 5 ×  1075 M  2-mercaptoethanol,  1% nonessential amino acids, 
1% sodium  pyruvate,  and  1%  antibiotic-antimycotic.  All cultures  were incubated  for 4  d  at 
37°C  in a  water-saturated  atmosphere  of 10%  CO2  in air.  Proliferation  was assessed  by  the 
addition of 1 #Ci [SH]thymidine (10 Ci/mM spac)  (ICN Pharmaceuticals,  Inc., Irvine, Calif.) 
to triplicate test wells during the last  16-18 h of culture. Test wells were harvested on a MASH 
II (Microbiological Associates, Walkersville, Md.). 
In mixed lymphocyte cultures, 5 ×  105 responding lymphocytes were cultured with 5 X  105 
irradiated  (2,000  rad)  allogeneic-stimulating  spleen  cells.  For  the  mixed  lymphocyte-tumor 
cultures,  5  ×  105  SjL/j  mesenteric  lymph  node  cells and  5  X  104  irradiated  (10,000  tad), 
syngeneic RCS were mixed. All cells were irradiated with a 6°Co source. In both culture systems, 
nonimmune lymphocytes were generated by incubating the appropriate responding cells with 
irradiated syngeneic lymphocytes in numbers equal to the added stimulator cells. Viability was 
determined by trypan blue exclusion. 
Fluorescence.  After two washes in HBSS, the in vitro primed responding lymphocytes (or, in 
some eases, RCS) were suspended  in HBSS to  1 ×  106 cells/ml. A  2.0% solution of fluorescein 
dissolved in distilled water was added to the cells. The cells were labeled in a final concentration 
of 0.027%  wt/vol  fluorescein  for  15  min  at  37°C.  They  were  washed  twice  in  HBSS  and 
suspended  in  RPMI-1640/10%  FCS  to  1  ×  106  cells/ml  and  used  immediately.  In  some 
preliminary experiments,  the particular  target  cell was  fluoresceinated  by incubation  in 6  X 
10  -2 g/ml euchrysine for 45 rain at 37°C. Both labeling procedures gave equivalent results. 
Target-Lymphocyte Binding Assay.  Targets at 1 X  10  v cells/ml and in vitro primed lymphocytes 
at  1 X  10~ ceils/ml, both  in  RPMI-1640/10%  FCS, were incubated  separately  at  30°C for 5 
rain. In most experiments the cultured lymphoeytes were labeled with fluorescein. However, in 
some preliminary experiments,  the target  cell was  labeled with  euchrysine.  1 ml of cultured 
lymphocytes was added to 1 ml of the target cells, and this was allowed to incubate at 30°C for 
another  10 min. The cells were then centrifuged for 5 min at  160 g (maximum) and then gently 
resuspended  in 0.5 ml of RPMI-1640/10%  FCS. The percentage of cultured lymphocytes that 
bound  to  a  particular  target  cell  was  counted  under  a  fluorescent  microscope  using  the 
appropriate barrier filters and excitation. 
Competition of Tumor-associated Binding with Monoclonal  Anti-Ia. 7 Antibody.  The RCS-LA 16 was 
preincubated on ice in anti-Ia.7 antibody or a control serum for 2 h at a  dilution of 1:1,000 in 
RPMI-1640/10%  FCA. The cell concentration was at  1 X  l0  T cells/ml. The control sera were 
normal SJL/J serum and the hybridoma anti-Thy  1.2 antibody. After one wash in HBSS, the 
sera-pretreated RCS-LA16 were used in the standard  lymphocyte-tumor binding assay. In this 
manner, the ability of monoclonal anti-Ia.7 serum to inhibit the lymphocyte-tumor interaction 
was assessed. 
The  anti-Ia.7  antibody  was  also  absorbed  on  several  normal  cell  populations  or  on  the 
RCS-LA16 to correlate Ia.7-directed antibody activity with inhibition of binding. One popu- 
lation that expresses Ia.7, CBA, was used in absorption. SJL/j and C57B1/6 spleen cells, which 
are both negative for Ia.7, were also used. In all eases, the absorption was at a  serum dilution 
of h 1,000 in RPMI-1640/10%  FCS and a  cell concentration of 5  X  l0  T lymphocytes/ml or 2 
X  107 RCS-LA16/ml. After 2 h on ice, the cells were centrifuged and the supernate was stored 
at -70°C. 
Calculation of Data.  All data  were expressed  as  the  difference between  the  percentage  of 
immune and nonimmune lymphocytes which bound to a particular target cell. The significance 
of binding above background levels was determined by the Student's t test and standard  errors 
were calculated using standard  formulas. 
Results 
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used to verify that both syngeneic and alien determinants are found on the in vivo 
passaged RCS. SJL/J lymph node cells were primed against H-2  a alloantigens by co- 
culturing for 4 d  with irradiated DBA/2 spleen cells.  Binding to normal spleen cells 
by these effectors can only be demonstrated against DBA/2 cells and not spleen cells 
of other  haplotypes.  In  addition,  these  same  anti-H2  a  effector lymphocytes bind 
significantly  to  the  in  vivo  passaged  RCS.  This  result  is  not  confined  to  SJL/J 
responding cells. When CBA spleen cells were primed with irradiated DBA/2  lym- 
phocytes, equivalent results were obtained (Table I). The binding of primed lympho- 
cytes  to  the  RCS  exhibits  antigenic  specificity  because  SJL/J  anti-H2  k  effector 
lymphocytes demonstrate significant binding against  only CBA spleen cells, and  in 
no instance can binding be found against  the RCS or normal spleen cells of other 
haplotypes (Table I). 
It was  of interest  to determine whether the  RCS  expressed its  appropriate  H-2  s 
determinants as well as those of the H-2  a haplotype. CBA spleen cells were co-cultured 
for  4  d  with  irradiated  SJL/J  lymphoeytes.  As  expected,  the  anti-H2  s  effeetor 
lymphocytes bound to normal SJL/J spleen cells.  Furthermore, they recognized and 
bound effectively the in vivo passaged RCS (Table I). These results show that the in 
vivo passaged RCS expresses its own syngeneic H-2  ~ molecules and also specificities 
of the H-2  a haplotype. 
Syngeneic Lymphocytes, Primed In  Vitro against the RCS, Recognize the Tumor and Allogeneic 
Specificities.  Normal SJL/J lymph node cells were co-cultured with irradiated RCS- 
LA16 for 4 d. Then their binding activity against the RCS or normal spleen cells was 
assessed.  When tested against the stimulating RCS-LA16, the in vitro primed effector 
lymphocytes recognize and bind significantly to the tumor (Table II). In agreement 
with previous work (7), in no instance could cytolysis be detected, against either the 
RCS-  or  H-2a-bearing cells,  by these  effector lymphocytes  (data  not  shown).  The 
binding to the tumor was highly reproducible. The percentage of primed lymphocytes 
which  bind  tumor  is  routinely  more  than  two  times  the  binding  observed  by 
nonimmune cultured lymphocytes. In addition, these same effector lymphocytes can 
recognize allogeneic DBA/2  specificities  (Fig.  1).  No  demonstrable activity can  be 
detected against  C57B1/10, CBA, or syngeneic SjL/j spleen cells.  These data indi- 
TABLE I 
Demonstration of Alien and Syngeneic Histocompatibility Determinants Expressed on RCS-LA 16 Using 
Alloreactive Lymphocytes 
Mixed lymphocyte cultures*  Targets of effector lymphocytes:~ 
C57Bl/10b 
Responder  Stimulator  Proliferation  RCS-1..AI6  DBA/2 (H2  d)  SJI,/(H2")  CBA (H2  k)  (H2t,) 
SJL/J  DBA/2  332,440 +  4,163  i 1.5 ±  1.5§  18.0 ±  1.8§  0  0  0.6 ±  3.0[[ 
CBA  DBA/2  68,004 ±  5,425  17.7 ±  2.6~  32.0 ±  IA§  4.0 ±  2.511  0  2.7 ::1:  2.71] 
SjL/j  CBA  457,509 ±  26,209  0  0  0  ~6.0 ±  0.0§  0.7 ±  1.911 
CBA  SJL/J  20,069 ±  2,682  21.0 ~  1.2§  0.6 ±  1.211  18.5 ±  x.3§  0.3 ±  1.211  0.3 ±  0.711 
* Mixed  lymphocyte  cultures  were incubated  for 4  d  with equal  numbers  of responding spleen  cells and  irradiated allogeneic spleen cell 
stimulators as described in Materials and Methods. 
All data represent percentage of binding ±  SE as expressed as the percentage of immune lymphocytes  minus the percentage of nonimmune 
lymphocytes  which bound  a  particular target. Percentage of nonimmune  binding for all SJl,/J effectors was 9,4 "¢- 3.~7~, and  for all CBA 
effectors was 10.4 -t- 2.2%. 
§ P<  o.005. 
II Not significant. STANLEY M.  WILBUR AND BENJAMIN BONAVIDA 
TABLE  II 
Recognition of the RCS-LA 16 by Tumor-activated Syngeneic Lymphocytes 
Mixed lymphocyte-  Proliferation*  Binding:l: 
tumor culture 
% 
Experiment 1  173,053 +  36,030  15.3 +  2.1§ 
Experiment 2  129,534 =l= 12,808  18.0 3= 2.9§ 
Experiment 3  157,179 3= 14,961  19.5 =t: 1.511 
* Mixed  lymphocyte-tumor  cultures  were  prepared  by  co-culturing  SJL/J 
lymph node cells with irradiated RCS-LAI6, as described in Materials and 
Methods. 
:]: The data are expressed as the percentage of binding of nonimmune lympho- 
cytes subtracted from the percentage of binding by immune lymphocytes + 
SE. Percentage of binding by nonimmune lymphocytes averaged 9.7 =l= 3.5% 
in all three experiments. 
§ e < o.oo5. 
II P <  0.0005. 
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Fro.  1.  Specificity of recognition by syngeneic  tumor-activated lymphocytes.  The percentage of 
nonimmune  binding  to  all  targets  was  11.1  3=  3.2%. All  data  is  presented  with  background 
nonimmune binding subtracted from the percentage of binding by immune cells. The significance 
of binding to the RCS-LA  16 and DBA/2 spleen cells was P < 0.0005 as determined by the Student's 
t test. These results are representative of three separate experiments. 
cated that  the alien  H-2  d specificities present on the  RCS  are  directly involved in 
syngeneic effector cell recognition of the tumor. 
This alien histocompatibility-associated recognition by syngeneic anti-RCS effector 
lymphocytes is not confined to the in vivo passaged RCS-LA16. An in vitro cultured 
line,  RCS-LA6b,  and  a  primary  spontaneous  tumor,  RCS-LA30,  give  equivalent 
results. As was the case with RCS-LA16, syngeneic lymphocytes primed against either 
of these  tumor  lines  can  recognize both  the  tumor  and  normal  DBA/2  antigens. 
Again,  no binding is evident against  C57B1/10, CBA, or SjL/j  spleen cells  (Table 
III). 
Alien  Specificities Detected by  SJL/J  Anti-RCS Effector Lymphocytes Mimic  Hybrid  Ia 
Determinants of the d Haplotype.  Congenic recombinant mice were used to determine 
the  regions  of  the  H-2  d  genome  that  encode  the  alien  specificities  recognized  by 
SJL/J  anti-RCS  effector cells  (see Table  IV for haplotypes).  B 10.D2  spleen cells are 
significantly  bound  by  the  effector  lymphocytes.  No  detectable  activity  can  be 
demonstrated against B 10.BR spleen cells (Fig. 2). These results were expected because 
previously H-2  d, yet not  H-2 k, specificities were shown  to be involved. The  data also 
indicated  that  non-H2-encoded  gene products do not play a  role in the binding.  The 506  HYBRID  Ia  MOLECULES  ON  RETICULUM  CELL  SARCOMAS 
TABLE  III 
Identification of Alien Determinants on Cultured and Spontaneous RCS 
Mixed lymphocyte-tumor 
cultures* 
Targets of effector lymphocytes~ 
Stimula-  Proliferation  RCS-LA6b  RCS-LA30  DBA/2  SJL/J  CBA  C57Bl/10 
tor  (H2  a)  (H2")  (H2  k)  (H2  b) 
RCS-LA6b  38,128  +  2,647  23.6 +  1.9§  ND  13.7 ±  2.5§  0  0  0 
RCS-LA30  27,423  ±  4,162  NDI]  10.2 ±  1.5§  12.8 ±  2.0§  0  0  0 
* These cultures were set up as described in Materials and Methods. 
All data were expressed as percentage of binding of nonimmune cells subtracted from the percentage of 
binding with immune lymphocytes. Nonimmune binding averaged  12.1 +  2.6%. 
§ P <  0.005. 
]1 ND, not done. 
TABLE  IV 
H-2 RegwnsofRecombinantStramsUsed 
Strain  K  D  Binding 
IA  IB  U  IE  IC 
C57B1/10,  C57B1/6  b  b  b  b  b  b  b  - 
DBA/2, B 10.D2  d  d  d  d  d  d  d  + 
CBA, B 10.BR  k  k  k  k  k  k  k  - 
SJL/J, B10.S  s  s  s  s  s  s  s  - 
B10.OL  d  d  d  d  d  d  k  + 
B10.A  k  k  k  k  k  d  d  - 
D2.GD, B 10.GD  d  d  b  b  b  b  b  - 
(B10.A  ×  B10.GD)F1  k/d  k/d  k/b  k/b  k/b  d/b  d/b  + 
BI0.S(9R)  s  s  ND*  k  k  d  d  + 
* Not defined. 
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FIG.  2.  Genetic  mapping to the  I  region of alien  determinants recognized  by syngeneic tumor- 
activated  lymphocytes. The percentage of nonimmune binding to all  targets was 9.1  +  2.7%. All 
data  are  presented  with  percentage  of nonimmune binding  subtracted  from  the  percentage  of 
binding by immune cells. Two representative experiments are shown in solid histograms (experiment 
1), and slashed histograms (experiment 2). In experiment  l, the significance of binding to B10.D2 
targets was P<  0.0005  and to BI0.OL targets it was P<  0.005.  In experiment 2, the significance of 
binding to B10.D2  targets was P<  0.005 and to B10.OL targets it was P< 0.0005.  No other targets 
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effector cells can bind to spleen cells of the H-2  d haplotype, regardless of the non-H2 
background genes of the particular strain. The data also show that antigen recognition 
of SJL/J anti-RCS lymphocytes does not exhibit the H-2-restricted recognition that 
is  normally  associated  with  syngeneic  "modified  self"  responses.  The  recognitive 
process seems more allied to that seen by alloreactive lymphocytes. 
BI0.A spleen cells  are not recognized by the SJL/J anti-RCS effector cells.  Thus, 
IC  d through D d region products are not involved in the binding process. Conversely, 
the effector cells  do bind to B10.OL spleen cells.  The molecules that are recognized, 
consequently, are encoded somewhere between the K d and IE  d regions. On the other 
hand, D2.GD spleen cells  are not recognized (Fig.  2).  This finding eliminates those 
products  encoded  within  K  or  IA as  relevant.  It  does  not,  however  exclude  the 
possibility  of a  hybrid  Ia  molecule  that  contains  an  IA-encoded component.  The 
D2.GD  (or  B10.GD)  strain  does  not  synthesize the  complementary IE component 
(11). Thus, no hybrid Ia molecules are expressed. 
The possibility of hybrid Ia molecules expressed on the RCS was examined.  Both 
B10.A and B10.GD spleen cells were not recognized by the SJL/J anti-RCS effector 
lymphocytes. Nevertheless, the effector cells  did recognize an F1 hybrid of these two 
strains. (B 10.A ×  B 10.GD)F1 spleen cells are recognized to an extent equivalent to the 
B10.D2  strain  (Fig.  3).  These  transcomplementation  data  indicate  that  the  SJL/ol 
anti-RCS effector cells recognize a hybrid Ia molecule. The F1 animal derived an IA  d- 
encoded  product  from  the  B10.GD  parent  and  an  IEk-encoded product  from  the 
B10.A parent. These two products associate on the cell membrane of the F1 animal 
and cross-react in the binding assay with the IAdIE  d hybrid found in mice of the H-2  d 
haplotype. These results also indicate that IAklE  k hybrid Ia molecules do not cross- 
react because B10.A, B10.BR, or CBA spleen cells  are not recognized by the SjL/j 
anti-RCS effector lymphocytes. 
Further evidence that the SJL/,J anti-RCS effectors recognize a hybrid Ia molecule 
was obtained using a roonoclonal anti-Ia.7 antibody. The Ia.7 specificity is present on 
the IE component of hybrid Ia molecules, regardless of their haplotype. Consequently, 
if the SjL/j anti-RCS effector cells recognize a hybrid Ia molecule on the tumor, this 
antibody should inhibit the binding. This was found to be the case (Table V). When 
RCS-LA16 was preincubated with anti-Ia.7, recognition of this tumor by SJL/J anti- 
20 
7o  ~2 
8 
4 
0 
B(O.D2  (BIO.A  x  BfO.A  BlO.GO 
EItO GD)FI 
TARGETS 
FIG. 3.  Determination that hybrid Ia molecules are  recognized by tumor-activated syngeneic 
lymphocytes. The percentage of nonimmune binding to all targets averaged 12.8 +  1.6%. In all 
data, the background nonimmune binding was subtracted from immune effector cell binding. 
Experiment  I  (solid histograms) and experiment 2 (slashed histograms) are two representative 
experiments. The  significance of binding in  both experiments to  the  B10.D2 and  (BI0.A x 
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TABLE  V 
Inhibition of Lymphocyte to RCS Binding by Monoclonal Anti-Ia. 7 Antibody 
Sera*  Absorbed on  Binding~ 
Experiment 1 
% 
--  --  20.3 ±  2.7§ 
Anti-Thy 1.2  --  22.7 ±  1.6§ 
Normal mouse serum  --  17.0 ±  0.8§ 
Anti-Ia.7  --  2.2 ±  1.5 
Experiment 2  --  --  21.1  ±  1.5§ 
Anti-Ia.7  --  0.6 ±  1.1 
Anti-Ia-7  CBA  16.8 +  0.9§ 
Anti-la.7  C57B1/6  1.4 ±  1.4 
Anti-Ia.7  SJL/J  0 
Anti-Ia.7  RCS-LA16  18.4 ±  0.8§ 
* Antibody treatment and absorptions on normal lymphocytes or RCS were 
performed  as  described  in  Materials  and  Methods.  Two  representative 
experiments are shown. 
:~ All  data were expressed as  the percentage of immune binding minus the 
percentage of nonimmune binding. Background nonimmune binding aver- 
aged  13.2 ±  2.8% in experiment 1 and 15.2 ±  2.3% in experiment 2. 
§ P < 0.0005. 
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FIG.  4.  Binding of SJL/J anti-RCS effector lymphocytes to B10.S(9R)  spleen cells. Background 
percentage  of  nonimmune  binding  to  all  targets  averaged  12.1  _  2.5%. The  percentage  of 
nonimmune binding was subtracted from the percentage of binding by immune effector cells. Two 
representative experiments (solid  and slashed histograms) are presented.  Significance of binding 
over nonimmune levels was P <  0.0005  for the targets RCS-LA16 and B10.S(9R).  No other target 
showed significant binding. 
tumor  effector cells  is  completely abrogated.  Neither  normal  SJL/J  serum  nor  a 
hybridoma anti-Thy 1.2 antibody is inhibitory as a control. The blocking activity is 
completely removed by preabsorbing the antibody on CBA spleen cells, which bear 
Ia.7. Conversely, C57B1/10 spleen cells, which do not synthesize an IE product and 
thus do not express Ia.7,  cannot  remove  the blocking activity.  Normal  SJL/J  spleen 
cells  also  do  not  make  an  IE  product,  so  they  fail  to  absorb  any  blocking activity. 
However, the RCS-LA16  can absorb the blocking activity as well as CBA spleen cells. 
Thus,  the  RCS  differs  from  the  SJL/J  host  in  its  expression  of an  Ia.7-containing 
polypeptide  that  is  probably  encoded  within  IE  and  is  the  a-chain  of a  hybrid  Ia 
molecule. 
SJL/J  cells  can  normally  synthesize  the  IA-encoded  product  of  the  hybrid  Ia 
molecule.  However,  the polypeptide  is not expressed on the membrane  because H-2  s 
animals do not synthesize the complementary  IE-encoded component.  Since the RCS STANLEY  M.  WILBUR AND  BENJAMIN  BONAVIDA  509 
can synthesize an IE-like product, it would be expected that the IA  8 component would 
also  be  expressed  on  the  tumor.  This  hypothesis  was  tested  using  the  congenic 
recombinant strain  B10.S(9R).  This animal expresses  a  hybrid Ia molecule in  the 
form of IA~IE  k. B 10.S(9R)  spleen cells are recognized by the SJL/J anti-RCS effector 
lymphocytes to an extent equal to the recognition of RCS-LA16 (Fig. 4). As controls, 
neither  B10.S  nor  B10.A  spleen  cells  were  recognized.  Thus,  the  alien  hybrid  Ia 
molecule expressed on the RCS that is recognized by the SJL/J anti-tumor effector 
lymphocytes probably consists of an IAS-encoded H-chain in association with an IE- 
encoded a-chain of unknown, and probably irrelevant, haplotype. 
Discussion 
The results of this study reveal that RCS-primed syngeneic lymphocytes recognize 
the alien H-2 antigens expressed on the tumor. Furthermore, the anti-tumor immune 
response is directed against specificities found on hybrid Ia molecules ofmurine strains 
bearing  H-2  °.  In  addition  to  H-2  °  determinants,  the  host  anti-tumor  responding 
lymphocytes were also shown to recognize hybrid Ia molecules from mice bearing 
several other cross-reactive haplotypes. One such murine strain, B10.S(9R), synthe- 
sized a  hybrid Ia molecule that consisted of a H-chain of the s haplotype and an a- 
chain of the k haplotype (Fig. 4). This last result was significant. Normal SJL/J cells 
synthesize the H-chain of the hybrid Ia molecule. However, it is not expressed because 
of their inability to synthesize a complementary a-chain (11). The data suggest that 
the RCS can synthesize an a-chain and consequently expresses both this a-chain and 
the fl-chain in the form of a hybrid Ia molecule. 
Since  the  SJL/J  anti-RCS  effector lymphocytes are  not  cytotoxic, our  studies 
assessed  antigen recognition by quantitating lymphocyte-target cell adhesions. Al- 
though it is well documented for cytotoxic T  lymphocytes (14,  15), noncytotoxic T 
lymphocytes have rarely been shown to bind to cell membrane-associated antigens. In 
guinea pigs (16,  17) and mice (18), antigen-pulsed macrophages have been shown to 
bind  to  antigen-primed  T  lymphocytes.  In  both  systems  the  binding  has  been 
associated  with  lymphocyte recognition  9 f  products  of the  I  region  of the  major 
histocompatibility complex, in conjunction with antigen  (18,  19). Other work has 
demonstrated binding of alloprimed Ly 1+23  -  lymphocytes to liposomes bearing the 
stimulating allogeneic Ia antigens (20). These lymphocytes are presumably noncyto- 
toxic, as has been indicated by other investigators (21,  22). T  lymphocytes may not 
bind liposomes and intact cells identically. Consequently, lymphocyte-liposome inter- 
actions may not precisely represent interactions occurring between lymphocytes and 
target cells. 
Recent  data have  demonstrated that  at  least  two cell surface glycoproteins are 
encoded within the I  region. Both proteins consist of two noncovalently associated 
polypeptides, a heavy a-chain and a light H-chain (9, 10, 13, 23, 24). One Ia molecule 
is a  product exclusively of the IA subregion and is expressed in all murine strains. 
Each chain of the other Ia molecule is synthesized in different I subregions. The fl- 
chain is synthesized within IA; however, the IE subregion encodes the a-chain. Unlike 
the other Ia polypeptides, this chain is not synthesized in all murine strains. Animals 
bearing the H-2  b or H-28 haplotypes do not synthesize the a-chain (11). Consequently, 
they do not express the hybrid Ia molecule even though synthesis of the H-chain is 
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Unlike  normal  SJL/J  cells,  the  RCS  does appear to synthesize an a-chain.  The 
exact  mechanism  by  which  this  chain  is  synthesized  in  the  RCS  is  completely 
unknown.  It may be that in normal SJL/J mice the genes encoding the a-chain are 
repressed.  Upon  oncogenesis,  there  is  a  loss  of regulation  which  permits  a-chain 
synthesis. Since all a-chains are nearly identical (10), it cannot be determined whether 
the derepressed genes encode a syngeneic H-2" product or one that is allogeneic. 
Synthesis of an a-chain by the RCS would  permit expression of the IA'-encoded 
/~-chain in the form of a hybrid Ia molecule. This Ia molecule would be recognized as 
foreign by the SjL/j  host  and could  induce an immune response analogous to one 
elicited in mixed lymphocyte cultures by Ia differences alone. In fact, both responses 
are similar in demonstrating only proliferation of Ly  1+23  -  T  lymphocytes, and no 
detectable cytotoxicity in primary cultures (5, 21, 22). 
This  mechanism  of antigen  presentation  and  host  recognition  assumes  that  the 
hybrid Ia molecules exhibit a relative extensive cross-reactivity. Peptide digest analysis 
of purified a-chain has revealed that there is little or no difference between polypep- 
tides encoded from different haplotypes (10).  Thus, antigenic determinants found on 
the a-chain would be shared by all haplotypes. Cross-reactivity between fi-chains has 
also  been  found.  In  the  context  of the  GL-Phe  immune  response,  murine  strains 
encoding fi-chains of the d, s, or b  haplotypes all show  high responses. Conversely, 
animals that express a ~-chain of the k haplotype or no hybrid Ia molecule are low 
responders (25-28). The serologically defined Ia. 22, specificity is expressed on animals 
encoding a/~-chain of the k, b, or s haplotypes. In contrast, the d haplotype expresses 
the  Ia.23  specificity  (29,  30).  Thus,  it  seems  that  the  pattern  of cross-reactivities 
observed among haplotypes is entirely dependent upon the assay system employed. 
Previously, little had been known of the RCS tumor antigens to which the SJL/J 
host responds.  Earlier work had indicated  that Ia molecules of the RCS of the H-2  s 
haplotype (i.e., those expressing Ia.4) were implicated (8).  However, interpretation of 
the data was difficult. It could not be determined whether the observed inhibition of 
the  anti-RCS  proliferative response by anti-Ia.4  antibody  was  due  to  blockage of 
antigen recognition or inhibition of the cooperation between responding cells. Thus, 
it is by no means conclusive that Ia molecules expressed on normal SJL/J cells are the 
antigenic determinants on the RCS to which the host responds. It is possible, however, 
that both IA-encoded/~-chains contain the Ia.4 specificity. If this were the case, then 
it could be expected that anti-Ia.4 antisera would block the response via interaction 
with the ~-chain component of the hybrid Ia molecule. 
Recently, another approach has been used to analyze the antigens involved in the 
syngeneic anti-RCS response (31).  In this study, the F1 offspring of a mating between 
SJL/J and several other strains were assessed for their ability to exhibit an anti-RCS 
proliferative  response.  Although  the  role  of hybrid  Ia  molecules  was  not  directly 
mentioned in the text, there was a correlation between hybrid Ia expression in the Fx 
animal  and  recognition  of  the  RCS  as  "self"  with  no  subsequent  induction  of 
proliferation. Conversely, in the F1 animals that did not express hybrid Ia molecules, 
there was marked anti-RCS responsiveness, as would be expected, due to recognition 
of "foreign"  Ia  determinants.  Consistent  with  our  conclusion,  their  data  strongly 
suggested that  hybrid Ia molecules, which contained the IA~-encoded fi-chain com- 
ponent, were immunogenic and induced the host anti-RCS proliferative response. 
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cultured  lines is cross-contamination with cells allogeneic to the host.  Conceivably, 
the RCS could be a  mixture or fusion product of SJL/J sarcoma cells and allogenic 
cells expressing H-2  a antigens.  If one assumes that the SJL/J mice are from a  pure 
strain, then primary tumors should be free of any contamination. The data presented 
evidence that  primary tumors and  transplantable  lines  gave equivalent  results  (see 
Table III). Further serological studies have shown the alien Ia.7 specificity on primary 
and transplantable  RCS,  but  not  on  normal SJL/J  lymphocytes (S.  Wilbur et  al., 
manuscript  in  preparation).  RCS-LAI6 was  also  analyzed  biochemically for poly- 
morphic  variants  of phosphoglucomutase  and  glutathione  reductase  (32,  33).  The 
results showed conclusively that RCS-LA16 was solely of SJL/J origin. There was no 
evidence of cross-contamination with any of the known murine strains which express 
H-2  a antigens. 
In  conclusion,  our  results  demonstt'ate  that  the  RCS  expresses  alien  hybrid  Ia 
molecules.  Furthermore,  we  propose  that  the  RCS,  unlike  the  host,  is  capable of 
synthesizing  the  a-chain  component  of the  hybrid  Ia  molecule.  The a-chain  then 
associates on the cell membrane with a syngeneic, but normally unexpressed, fi-chain 
to  form  a  molecule  recognized  as  foreign  by  the  host.  Consequently,  syngeneic 
lymphocytes respond  to the  tumor in  a  manner similar to that  observed  in  mixed 
lymphocyte  cultures  against  only  I  region  differences.  The  hybrid  Ia  molecule 
expressed on the RCS is also sufficiently similar to the one encoded in mice expressing 
H-2 a,  so that  there  is  strong cross-reactivity both  serologically and  cellularly.  This 
accounts for the observed alien H-2  a specificities previously reported to be expressed 
on the RCS cell surface (1, 2). 
Summary 
SJL/J  (H-2  s)  lymphocytes, primed in  vitro against  primary, cultured,  and trans- 
plantable syngeneic reticulum cell sarcomas (RCS) were found to recognize and bind 
to the tumor without subsequent cytolysis. Additional data showed that the recogni- 
tion  was  also  directed  against  Ia molecules of the  H-2  d,  but  not  H-2  k,  haplotype. 
Normal spleen cells of DBA/2, B 10.D2, and B 10.OL mice were bound, whereas those 
of CBA, B 10.BR, B 10.A, B 10.GD, and D2.GD were not. Furthermore, the Ia molecules 
were in the form of a  hybrid, because spleen cells from FI progeny of a  B10.A and a 
BI0.GD parent  were recognized and  bound  as effectively as the RCS.  Recognition 
was  not  restricted  solely to  the  H-2  a haplotype.  Spleen  cells from B10.S(9R)  mice 
were also significantly bound. This result suggested that the RCS expresses a  hybrid 
Ia molecule containing a/~-chain of the H-2  s haplotype. Recognition of this hybrid Ia 
molecule  by  the  host  resulted  in  a  cross-reactive  recognition  of H-2  a  specificities. 
Further analysis revealed that the RCS express on their cell surface an a-chain of the 
hybrid Ia molecule which  is involved in host anti-tumor recognition.  Preincubation 
of the RCS with monoclonal antibody directed against the Ia.7 specificity on the a- 
chain could block lymphocyte-to-tumor cell binding.  The blocking activity could be 
removed by preabsorption of the antibody on the RCS, as well as normal Ia.7-bearing 
lymphocytes, but not on lymphocytes that do not express Ia.7, such as SjL/j. 
The data suggest that the hybrid Ia molecules expressed on the RCS, and recognized 
by tumor-primed syngeneic lymphocytes, are composed of both a  syngeneic and an 
alien  chain.  The  component  alien  to  the  SJL/J  host  is  the  Ia.7-bearing e~-chain. 
Normal SJL/J cells synthesize but do not express the fl-chain. In the RCS, however, 512  HYBRID  Ia MOLECULES  ON  RETICULUM  CELL SARCOMAS 
alien a-chain synthesis permits expression of the syngeneic/~-chain in the form  of a 
hybrid Ia molecule. 
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